Today: 18 November 2025
Subscribe
Browse Category

Health Alerts News 11 August 2025 - 10 November 2025

E. coli Alert: France Recalls Reblochon de Savoie AOP Sold at E.Leclerc, Grand Frais and Fresh — What to Check Now (November 10, 2025)

E. coli Alert: France Recalls Reblochon de Savoie AOP Sold at E.Leclerc, Grand Frais and Fresh — What to Check Now (November 10, 2025)

Updated: November 10, 2025 — Nationwide (France) Key points at a glance What’s being recalled today 1) E.Leclerc — “Nos Régions ont du Talent” 2) Grand Frais & Fresh — Reblochon de Savoie AOP (Masson) How to spot the right product quickly: Check the brand, lot number, DLC (use-by date), GTIN (barcode), and the oval health stamp (FR 74.145.050). If any of these match the details above, treat the cheese as affected by the recall. Rappel Consommateur+1 Why are these cheeses recalled? The two recalls were issued after the presence/detection of E. coli STEC O26 was identified. Shiga toxin–producing E.
10 November 2025
 ·  ·  ·  · 
ALERT: Costa Rica Tourism Faces Turbulence – Airlines Cut Routes, Yellow Fever Strikes, and What It Means for Flights, Finance & Forecasts

ALERT: Costa Rica Tourism Faces Turbulence – Airlines Cut Routes, Yellow Fever Strikes, and What It Means for Flights, Finance & Forecasts

Airline Route Shifts and New Flights Costa Rica’s tourism hub remains highly dependent on air connectivity, and the fall 2025 shuffle is dramatic. Several major Latin American carriers have pulled back amid tightening margins. For example, Brazil’s GOL Linhas Aéreas (which launched a San José–São Paulo flight only last Nov.) will terminate that route on Nov 29 ticotimes.net. GOL cited a “network realignment” in a press statement. Colombia’s Wingo (a low-cost LATAM spinoff) is ending its Bogotá–San José service after Oct 28, also blaming capacity adjustments ticotimes.net. Avianca, Costa Rica’s longstanding flag-carrier, is cutting Central America ties: it will stop San José–San Juan
14 October 2025
 ·  ·  ·  ·  ·  · 
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Novartis announced that two Phase III trials, NEPTUNUS-1 and NEPTUNUS-2, met their primary endpoints in Sjögren’s disease, marking the first global Phase III evidence of significant disease activity reduction with ianalumab and its dual B-cell depletion and BAFF signaling blockade. IO Biotech will disclose topline results from its Phase III melanoma trial of Cylembio (IO102-IO103) in combination with Merck’s Keytruda (pembrolizumab) as a first-line therapy, with an August 11 webcast planned and the therapy having earned Breakthrough Therapy designation. GSK’s gepotidacin received Priority Review from the U.S. FDA for uncomplicated gonorrhea, with a decision expected by December and the potential
11 August 2025
 ·  ·  ·  · 
Go toTop